MSDS Cryopreserved Cells
Instructions CnOb
Cell Apps Flyer Skeletal System Cells
5 Important Cell Culture Rules
Cell Apps Poster Primary Cells
Cell Applications Inc Brochure

Description

Canine Osteoblasts (CnOb) from Cell Applications, Inc. provide an excellent model system for studies relevant to the skeletal system, including mechanisms of cancerogenesis.
Our CnOb. have been used to:
  • Define a biomarker profile of canine osteosarcoma, elucidate the roles of oncogenic STAT3 and canonical Wnt signaling pathways
  • Develop personalized osteosarcoma treatments by testing Src inhibitor dasatinib, procaspase-3 activating compound PAC-1, HSP90 inhibitor STA1474 and STAT3 inhibitor LLL12.
Characterization: Positive for bone mineralization

(Click to Enlarge) Canine Osteoblasts, CnOb (L) von Kossa stained (R).

Details

Tissue
Normal healthy canine bone.
QC
No bacteria, yeast, fungi, mycoplasma
Character
Bone mineralization (von Kossa stain)
Bioassay
Attach, spread, proliferate in Growth Med
Cryovial
500,000 CnOb (1st passage) frozen in Basal Medium w/ 10% FBS, 10% DMSO
Kit
Cryovial frozen CnOb (Cn406-05), Growth Med (Cn417-500), Subcltr Rgnt Kit (090K)
Proliferating
Shipped in Gr Med, 2nd psg (flasks or plates)
Doublings
At least 10 
Applications
Laboratory research use only (RUO). Not for human, clinical, diagnostic or veterinary use.
Instructions CnOb

Format: PDF

Download Now
MSDS Cryopreserved Cells

Format: PDF

Download Now

Products

Product Size CAT.# Price Quantity
Cryopreserved Canine Osteoblast Total Kit: 5x10^5 Cells, Medium & Subculture Reagents (See Details tab for specifics) Size: 1 Kit CAT.#: Cn406K-05 Price: $961.00
-+
Cryopreserved Canine Osteoblasts (CnOb): Frozen CnOb (5x10^5) Size: 1 Cryovial CAT.#: Cn406-05 Price: $775.00
-+
Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium Size: T-25 Flask CAT.#: Cn407-25 Price: $775.00
-+
Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium Size: T-75 Flask CAT.#: Cn407-75 Price: $965.00
-+
Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium Size: 24 Well CAT.#: Cn407-24W Price: $965.00
-+
Proliferating Canine Osteoblasts (CnOb): Actively growing, dividing cells in medium Size: 96 Well CAT.#: Cn407-96W Price: $1,085.00
-+

Related Products

Product Size CAT.# Price Quantity
CnOb Basal Medium: Basal medium (contains no growth supplement).  Add GS before use. Size: 500 ml CAT.#: Cn416-500 Price: $81.00
-+
CnOb Growth Medium: All-in-one ready-to-use Size: 500 ml CAT.#: Cn417-500 Price: $133.00
-+
CnOb Growth Medium Kit: Basal medium & growth supplement sold together packaged separately Size: Yields 500ml CAT.#: Cn417K-500 Price: $144.00
-+
CnOb Differentiation Medium: Promotes cells to change from one type to another, more specialized Size: 250 ml CAT.#: Cn417D-250 Price: $92.00
-+
CnOb Growth Supplement: Added to Basal Medium to create Growth Medium Size: 30 ml CAT.#: Cn417-GS Price: $81.00
-+

Extended Family Products

Product Size CAT.# Price Quantity
Subculture Reagent Kit: 100 ml each of HBSS, Trypsin/EDTA & Trypsin Neutralizing Solution Size: 1 Kit CAT.#: 090K Price: $63.00
-+

Resources/Documents

Cell Apps Flyer Skeletal System Cells

Format: PDF

Downoad Now
5 Important Cell Culture Rules

Format: PDF

Downoad Now
Cell Apps Poster Primary Cells

Format: PDF

Downoad Now
Cell Applications Inc Brochure

Format: PDF

Downoad Now

Publications

2017

Troyer RM, Ruby CE, Goodall CP, Yang L, Maier CS, Albarqi HA, Brady JV, Bathke K, Taratula O, Mourich D, Bracha S. 2017. Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Exp Cell Res. pii: S0014-4827(17)30365-8.

Murahari, S., A. Jalkanen, S. ulp, C. Chen, J. Modiano, C. London and W. Kesseberth. 2017. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer, 17:67.
2016
Fenger, J., R. Roberts, O. Iwenofu, M. Bear, X. Zhang, J. Couto, J. Modiano, W. Wisseberth and C. London. 2016. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines. BMC Cancer, 16:784.
González-Miguel, J., C. Larrazabal, D. Loa-Mesón, M. Siles-Lucas, F. Simón and R. Morchón. 2016.  Glyceraldehyde 3-phosphate dehydrogenase and galectin from Dirofilaria immitis participate in heartworm disease endarteritis via plasminogen/plasmin system. Veterinary Parasitology, 223:96-101. 
2015
de Sá Rodrigues, L., K. Holmes, V. Thompson, C. Piskun, S. Lana, M. Newton and T. Stein. 2015.  Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns. DOI: 10.1111/vco.12132.
2014
Quintanilha, L., T. Takami, Y. Hirose, K. Fujisawa, Y. Murata, N. Yamamoto, R. Goldenberg, S. Terai and I Sakaida. 2014. Canine mesenchymal stem cells show antioxidant properties against thioacetamide-induced liver injury in vitro and in vivo. Hepatology Res, 44:E206-E217.
2013
Couto, J. 2013. Biologic Activity of the Novel Small Molecule STAT3 Inhibitor Against Canine Osteosarcoma Cell Lines. The Ohio State University, M.Sc. dissertation.
Davis, L.E., N.E. Hofmann, G. Li, E.T. Huang, M.M. Loriaux, S. Bracha, S.C. Helfand, J.E. Mata, K. Marley, and A. Mansoor. 2013. A case study of personalized therapy for osteosarcoma. Pediatric blood & cancer. 60:1313-1319.
Milovancev, M., I. Hilgart-Martiszus, M.J. McNamara, C.P. Goodall, B. Seguin, S. Bracha, and S.I. Wickramasekara. 2013. Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts. BMC veterinary research. 9:116.
Piskun, C.M., and T.J. Stein. 2013. β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour. Vet. & Comp. Oncology: doi: 10.1111/vco.12077.
2012
Book, A.P. 2012. Investigating procaspase-3 as a potential therapeutic target in canine osteosarcoma. Master of Science Thesis. University of Illinois.
Couto, J.I., M.D. Bear, J. Lin, M. Pennel, S.K. Kulp, W.C. Kisseberth, and C.A. London. 2012. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC veterinary research. 8:244.
2011
Fossey, S., M. Bear, W. Kisseberth, M. Pennell, and C. London. 2011. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC cancer. 11:125.
McCleese, J. 2011. Investigating the Biological and Biochemical Consequences of Met Function and Dysfunction in Canine Osteosarcoma. PhD Dissertation, The Ohio State University.
2010
Fossey, S. 2010. Characterization of STAT3 Activation in Osteosarcoma. PhD Dissertation, Ohio State University.
2009
Fossey, S.L., A.T. Liao, J.K. McCleese, M.D. Bear, J. Lin, P.-K. Li, W.C. Kisseberth, and C.A. London. 2009. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC cancer. 9:81.
McCleese, J.K., M.D. Bear, S.L. Fossey, R.M. Mihalek, K.P. Foley, W. Ying, J. Barsoum, and C.A. London. 2009. The novel HSP90 inhibitor STA‐1474 exhibits biologic activity against osteosarcoma cell lines. Int. J.Cancer. 125:2792-2801.